Description
Salbutamol 4 mg
Brand: Magnus Pharmaceuticals
Content: 100 tablets | 4 mg per tablet
Price: €29
Manufactured in: Europe
🧪 Product Overview
Salbutamol 4 mg delivers a fast-acting β2-adrenergic agonist commonly used in airway research and cardiopulmonary modeling. Known in the U.S. as albuterol, this compound supports investigations into bronchodilation, exercise-induced asthma mitigation, airway-smooth-muscle signaling, and fat-loss models tied to β2 stimulation.
With onset in ~30 minutes and duration of 4–6 hours, oral salbutamol enables dynamic testing across acute and chronic studies. A 5–6 hour half-life supports twice-daily dosing in respiratory-performance trials, and its oral form simplifies lab handling over inhaler-based delivery.
✅ Key Research Highlights
Potent bronchodilation:
4 mg oral dose improves FEV₁ and FVC in mild asthma cohorts within 30 minutes [PubMed]
Respiratory-performance models:
Improved inspiratory capacity and reduced residual lung volume documented in exercise-based studies [PubMed]
Systemic β₂ activity:
Promotes intracellular potassium shift and raises heart rate — relevant for cardiometabolic modeling [Mayo Clinic]
Anti-doping relevance:
WADA bans all oral forms; only inhaled ≤1,600 µg/day permitted — tablet exposure triggers positive test [wada-ama.org]
Room-temperature stable:
Film-coated tablets retain potency at ≤25 °C for ≥36 months — better shelf life than inhaler solutions [nhs.uk]
🧬 Suggested Laboratory Applications
-
Bronchodilation and airway-smooth-muscle pharmacology
-
Exercise-induced asthma and VO₂-max modeling
-
β2-agonist thermogenic & fat-loss studies
-
Hypokalaemia and systemic electrolyte tracking
-
Cardiopulmonary performance and heart-rate stress simulations
📊 Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Salbutamol (INN) / Albuterol (USAN) |
| Chemical Formula | C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub> |
| Synonyms | Albuterol; (+/-)-Salbutamol; 1-(4-(tert-butylamino)-2-hydroxybenzyl)-2-(hydroxymethyl)-phenol |
| Molecular Weight | 239.31 g/mol |
| CAS Number | 18559-94-9 (base); 51022-70-9 (sulfate) |
| Half-life | ~5–6 hours (oral), onset ~30 min |
| Detection Window | ≥24 hours (oral), varies by dose |
| Documented Benefits | ↑ FEV₁, ↓ airway resistance, ↑ VO₂-max, thermogenic modeling |
| Main Risks | Tremor, tachycardia, hypokalaemia, insomnia, bronchospasm |
| Total Active Compound | 400 mg per carton (4 mg × 100 tablets) |
| Shelf-life | 36 months (manufacturer specification) |
❄️ PubChem-Supported Research Insights
-
Promotes rapid bronchodilation in obstructive lung models
-
Improves peak expiratory metrics (FEV₁, FVC) in dose-dependent trials
-
Shown to increase cardiac output and VO₂-max in heart-failure studies
-
Studied for thermogenic/lipolytic effects in β2-stimulation models
-
Oral route supports longer systemic effect and steady sampling
⚠️ Documented Research Side Effects
-
Common: Tremor, headache, insomnia, and tachycardia
-
Dose-related: Hypokalaemia due to potassium shift
-
Rare: Paradoxical bronchospasm during airway-sensitive protocols
-
Cardiovascular strain at elevated exposure
🧯 Handling & Compliance
For Research Use Only — Not for human or veterinary use
Store at 15–25°C, protect from light and moisture
Purchase confirms qualified researcher status
Listed under WADA S3 (β2-agonists) — oral exposure prohibited without TUE
There are no reviews yet.
